Nafarelin
Also referenced as: Synarel
An intranasal GnRH agonist used for selected endocrine suppression indications.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
Synarel is FDA-approved for endometriosis and central precocious puberty, subject to product-specific criteria.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
An intranasal GnRH agonist used for selected endocrine suppression indications.
Synarel is FDA-approved for endometriosis and central precocious puberty, subject to product-specific criteria.
Intranasal delivery does not make it a general libido or fertility enhancer.
Why It's Being Studied
- Endometriosis
- Central precocious puberty
Mechanism of Action
Sustained stimulation suppresses gonadotropin secretion following an initial flare.
Sustained stimulation suppresses gonadotropin secretion following an initial flare. Intranasal delivery does not make it a general libido or fertility enhancer.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Endometriosis
- Central precocious puberty
- Intranasal approved medicine
Evidence Summary
Clinical evidence supports endometriosis and central precocious puberty indications.
Higher tiers carry more weight. Filled tiers have evidence for Nafarelin; tap to read it.
- Clinical evidence supports endometriosis and central precocious puberty indications.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Clinical evidence supports endometriosis and central precocious puberty indications.
Reported Adverse Events in Research
- Bone loss, initial flare, nasal-delivery limitations and psychiatric or seizure warnings are important.
Limitations of Current Evidence
- Intranasal delivery does not make it a general libido or fertility enhancer.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Nafarelin | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Intranasal approved medicine | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Nafarelin — prescribing label